Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation

Acta Pharmacologica Sinica

Volumn 35, Issue 3, 2014, Pages 410-418

  Yang, Li ^a   Shi, Li Ping ^a   Chen, Hai Jun ^a   Tong, Xian Kun ^a   Wang, Gui Feng ^a   Zhang, Yang Ming ^a   Wang, Wen Long ^a   Feng, Chun Lan ^a   He, Pei Lan ^a   Zhu, Feng Hua ^a   Hao, You Hua ^b   Wang, Bao Ju ^b   Yang, Dong Liang ^b   Tang, Wei ^a   Nan, Fa Jun ^a   Zuo, Jian Ping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

adefovir; capsid assembly; entecavir; hepatitis B; isothiafludine; lamivudine; non nucleoside compound; pregenomic RNA; virus replication

Indexed keywords

ADEFOVIR; CORE PROTEIN; ENTECAVIR; HEPATITIS B CORE ANTIGEN; ISOTHIAFLUDINE; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NZ 4; PREGENOMIC RNA; RNA; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; THIAZOLE DERIVATIVE; VIRUS RNA;

AGAR GEL ELECTROPHORESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL RESISTANCE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DNA REPLICATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; GENE INTERACTION; HEPATITIS B; HEPATITIS B VIRUS; IC 50; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SYNTHESIS; SOUTHERN BLOTTING; VIRUS ASSEMBLY; VIRUS CAPSID; VIRUS INHIBITION; VIRUS MUTANT; VIRUS REPLICATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DUCK; DUCK HEPATITIS B VIRUS; GENETIC TRANSFECTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEPADNAVIRIDAE INFECTIONS; HEPATITIS, VIRAL, ANIMAL; HEPG2 CELL LINE; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; MUTATION; TIME; VIROLOGY; VIRUS NUCLEOCAPSID;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, VIRAL; DUCKS; HEP G2 CELLS; HEPADNAVIRIDAE INFECTIONS; HEPATITIS B VIRUS; HEPATITIS B VIRUS, DUCK; HEPATITIS, VIRAL, ANIMAL; HUMANS; MUTATION; NUCLEOCAPSID; RNA, VIRAL; THIAZOLES; TIME FACTORS; TRANSFECTION; VIRUS REPLICATION;

EID: 84895556462     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.175     Document Type: Article

References (23)

1. Grimm D, Thimme R, Blum HE. HBV life cycle and novel drug targets. Hepatol Int 2011; 5: 644-53.
2. Negro F. Management of chronic hepatitis B: an update. Swiss Med Wkly 2011; 141: w13264.
3. Leemans WF, Ter Borg MJ, de Man RA. Review article: success and failure of nucleoside and nucleotide analogues in chronic hepatitis B. Aliment Pharmacol Ther 2007; 26 Suppl 2: 171-82.
4. Lucifora J, Zoulim F. The life cycle of hepatitis B virus and antiviral targets. Future Virol 2011; 6: 599-614.
5. Choi IG, Yu YG. Interaction and assembly of HBV structural proteins: novel target sites of anti-HBV agents. Infect Disord Drug Targets 2007; 7: 251-6.
6. Chen HJ, Wang WL, Wang GF, Shi LP, Gu M, Ren YD, et al. Rational design and synthesis of 2,2-bisheterocycle tandem derivatives as non-nucleoside hepatitis B virus inhibitors. Chem Med Chem 2008; 3: 1316-21.
7. Deres K, Schroder CH, Paessens A, Goldmann S, Hacker HJ, Weber O, et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 2003; 299: 893-6.
8. Ying C, Li Y, Leung CH, Robek MD, Cheng YC. Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. Proc Natl Acad Sci U S A 2007; 104: 8526-31.
9. Wu C, Deng W, Deng L, Cao L, Qin B, Li S, et al. Amino acid substitutions at positions 122 and 145 of hepatitis B virus surface antigen (HBsAg) determine the antigenicity and immunogenicity of HBsAg and influence in vivo HBsAg clearance. J Virol 2012; 86: 4658-69.
10. Newman M, Chua PK, Tang FM, Su PY, Shih C. Testing an electrostatic interaction hypothesis of hepatitis B virus capsid stability by using an in vitro capsid disassembly/reassembly system. J Virol 2009; 83: 10616-26.
11. Porterfield JZ, Dhason MS, Loeb DD, Nassal M, Stray SJ, Zlotnick A. Full-length hepatitis B virus core protein packages viral and heterologous RNA with similarly high levels of cooperativity. J Virol 2010; 84: 7174-84.
12. Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A 1987; 84: 1005-9.
13. Tong XK, Qiu H, Zhang X, Shi LP, Wang GF, Ji FH, et al. WSS45, a sulfated alpha-D-glucan, strongly interferes with Dengue 2 virus infection in vitro. Acta Pharmacol Sin 2010; 31: 585-92.
14. Zhang X, Zhang E, Ma Z, Pei R, Jiang M, Schlaak JF, et al. Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology 2011; 53: 1476-85.
15. Guan SH, Lu M, Grunewald P, Roggendorf M, Gerken G, Schlaak JF. Interferon-alpha response in chronic hepatitis B-transfected HepG2.2.15 cells is partially restored by lamivudine treatment. World J Gastroenterol 2007; 13: 228-35.
16. Nguyen DH, Hu J. Reverse transcriptase-and RNA packaging signal-dependent incorporation of APOBEC3G into hepatitis B virus nucleocapsids. J Virol 2008; 82: 6852-61.
17. Chua PK, Wang RY, Lin MH, Masuda T, Suk FM, Shih C. Reduced secretion of virions and hepatitis B virus (HBV) surface antigen of a naturally occurring HBV variant correlates with the accumulation of the small S envelope protein in the endoplasmic reticulum and Golgi apparatus. J Virol 2005; 79: 13483-96.
18. Hu Q, Fang Y, Zhang ZM, Zhang XY, Zhang ZH, Yang DL. Establishment of an in vivo model for duck hepatitis B virus infection using Hubei duckling. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2008; 22: 113-5.
19. Schädler S, Hildt E. HBV life cycle: entry and morphogenesis. Viruses 2009; 1: 185-209.
20. Bourne CR, Finn MG, Zlotnick A. Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1. J Virol 2006; 80: 11055-61.
21. Bourne C, Lee S, Venkataiah B, Lee A, Korba B, Finn MG, et al. Small-molecule effectors of hepatitis B virus capsid assembly give insight into virus life cycle. J Virol 2008; 82: 10262-70.
22. Feld JJ, Colledge D, Sozzi V, Edwards R, Littlejohn M, Locarnini SA. The phenylpropenamide derivative AT130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res 2007; 76 168-77.
23. Katen SP, Chirapu SR, Finn MG, Zlotnick A. Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators. ACS Chem Biol 2010; 5: 1125-36.